Abzena PLC Notice of full year results (4087P)
29 May 2018 - 6:00PM
UK Regulatory
TIDMABZA
RNS Number : 4087P
Abzena PLC
29 May 2018
Abzena plc
Notice of full year results
Cambridge, UK, 29 May 2018 - Abzena plc (AIM: ABZA, 'Abzena' or
the 'Group'), a life sciences group providing services and
technologies enabling the development and manufacture of
biopharmaceutical products, will publish its full year results for
the year to 31 March 2018 on Monday, 4 June 2018.
A presentation for analysts will be held at 09:30am on 4 June
2018 at the offices of Instinctif Partners (65 Gresham Street,
London EC2V 7NQ).
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer Julian Smith, Chief
Financial Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / James Black +44 20 7260
/ Paul Gillam 1000
N+1 Singer (Joint Broker) +44 20 7496
Aubrey Powell / Liz Yong 3000
Instinctif Partners +44 20 7457
Melanie Toyne Sewell / Rozi 2020
Morris / Alex Shaw abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Biology research services, including immunogenicity
assessment of candidate biopharmaceutical products and bioassay
development;
-- Protein engineering to optimise biopharmaceutical product
candidates, including humanization and deimmunization of antibodies
and other therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and other
recombinant proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development;
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads; and.
-- GMP analytical services for biopharmaceutical manufacturing projects
For more information, please see www.abzena.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORDMGZKVKVGRZM
(END) Dow Jones Newswires
May 29, 2018 04:00 ET (08:00 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From Sep 2023 to Sep 2024